

<!--StartFragment-->RESULT 1

AAR26022

ID AAR26022 standard; peptide; 25 AA.

XX

AC AAR26022;

XX

DT 15-JUN-2007 (revised)

DT 25-MAR-2003 (revised)

DT 26-JAN-1993 (first entry)

XX

DE Peptide inhibiting juvenile hormone esterase.

XX

KW Insecticide; insect; Lepidoptera; plasma.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Disulfide-bond 7. .19

FT Modified-site 25

FT /note= "amidated"

XX

PN EP498222-A1.

XX

PD 12-AUG-1992.

XX

PF 23-JAN-1992; 92EP-00101084.

XX

PR 24-JAN-1991; 91JP-00025374.

XX

PA (SUMO) SUMITOMO CHEM CO LTD.

XX

PI Chino H, Hayakawa Y;

XX

DR WPI; 1992-270232/33.

DR PC:NCBI; gil25064.

XX

PT New peptide(s) inhibiting juvenile hormone esterase - useful as
 PT insecticides and regulators of insect development, esp. for control of
 PT Lepidoptera larvae.

XX

PS Claim 1; Page 1; 22pp; English.

XX

CC The peptide is an inhibitor of the enzyme juvenile hormone esterase, so
 CC is useful as an insecticide and/or for agents for controlling insect
 CC development, partic of Lepidoptera larvae. The peptide is present in the
 CC plasma of last instar larvae of the armyworm Pseudaletia separata,
 CC parasitised by the wasp Apanteles kariyai. It can be isolated by
 CC extracting the haemolymph with 25 percent EtOH then purified by gel
 CC permeation and reverse phase chromatography, or can be synthesised by
 CC standard peptide chemistry. (Updated on 25-MAR-2003 to correct PN field.)

CC

CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
 CC information from BOND.

XX

SQ Sequence 25 AA;

Query Match 100.0%; Score 146; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 3e-11;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ENFSGGCVAGYMRTPDGRCKPTFYQ 25

```

      ||||||||||||||||||
Db      1  ENFSGGCVAGYMRTPDGRCKPTFYQ 25
<!--EndFragment-->
```

<!--StartFragment-->RESULT 6

AAW37304

ID AAW37304 standard; peptide; 91 AA.

XX

AC AAW37304;

XX

DT 25-MAR-2003 (revised)

DT 06-MAR-1998 (first entry)

XX

DE Amphiregulin AR97-187.

XX

KW Heparin binding property; amphiregulin; mitogenic activity; wound;

KW skin condition; ulcer; bone disorder; cancer.

XX

OS Homo sapiens.

XX

PN WO9723507-A2.

XX

PD 03-JUL-1997.

XX

PF 23-DEC-1996; 96WO-EP005831.

XX

PR 22-DEC-1995; 95EP-00870138.

XX

PA (INNO-) INNOGENETICS NV.

XX

PI Delaey B, Raymackers J, Van Heuverswyn H;

XX

DR WPI; 1997-350971/32.

XX

PT Amphiregulin derived polypeptide(s) with mitogenic activity and heparin-binding properties - used to treat, e.g. wounds, skin conditions, ulcers, bone disorders or cancer.

XX

PS Claim 9; Page 5; 51pp; English.

XX

CC The presentsequence represents a novel amphiregulin AR97-187 which has mitogenic activity and heparin-binding properties. The polypeptide can be used for treating e.g. skin wounds (including burns, ulcers, surgical wounds, cicatrization), skin contractions, corneal wounds or defects, post-surgical treatment after tympanic membrane reconstructions, or other middle ear reconstructions, chronic otorrhea, intestinal or stomach ulcers, dermatological disorders, bone disorders, cancer (including colon, prostate, ovarium, pancreas), or any other illness state where an amphiregulin would be required or useful. Products can also be used for diagnosis and for manipulating the growth characteristics of epithelial cells in tissue cultures. (Updated on 25-MAR-2003 to correct PI field.)

XX

SQ Sequence 91 AA;

Query Match 100.0%; Score 467; DB 1; Length 91;

Best Local Similarity 100.0%; Pred. No. 3.5e-39;

Matches 84; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SVRVEQVVKPPQNKTESENTSDKPKRKKKGKNGKNRRNRKKKNPCNAEFQNFCIHGECK 60
 |||

Db 5 SVRVEQVVKPPQNKTESENTSDKPKRKKKGKNGKNRRNRKKKNPCNAEFQNFCIHGECK 64

Qy 61 YIEHLEAVTCKCQQEYFGERCGEK 84
 |||

Db 65 YIEHLEAVTCKCQQEYFGERCGEK 88

<!--EndFragment-->

```

<!--StartFragment-->RESULT 1
AAW04554
ID  AAW04554 standard; protein; 80 AA.
XX
AC  AAW04554;
XX
DT  22-JUL-1997 (first entry)
XX
DE  Human betacellulin protein.
XX
KW  Antibody; human; betacellulin; hBTC; growth factor; antagonist;
KW  neutralisation; biological activity; binding; sensitive; specific;
KW  therapy; treatment; disease; arterial sclerosis; cancer; reagent; assay;
KW  diagnosis; diabetes; low toxicity; antigen; epitope.
XX
OS  Homo sapiens.
XX
PN  WO9630506-A1.
XX
PD  03-OCT-1996.
XX
PF  22-MAR-1996; 96WO-JP000762.
XX
PR  24-MAR-1995; 95JP-00065577.
XX
PA  (TAKE ) TAKEDA CHEM IND LTD.
XX
PI  Sasada R, Watanabe T, Toyoda Y;
XX
DR  WPI; 1996-505784/50.
XX
PT  Antibody specific for human betacellulin protein (hBTC) - useful as
PT  therapeutic agent for arterial sclerosis and cancer, as it neutralises
PT  hBTC's biological activity, and as diagnostic agent for diabetes.
XX
PS  Claim 2; Page 58; 87pp; English.
XX
CC  The present sequence is a human betacellulin protein (hBTC), which
CC  comprises residues 32-111 of the human BTC growth factor protein
CC  AAR40168. An antibody (Ab) which specifically binds the present sequence
CC  can be used to neutralise the biological activity of hBTC, and bind the
CC  protein with high sensitivity and specificity. The Ab can also be used as
CC  a therapeutic agent for diseases such as arterial sclerosis and cancer,
CC  as a reagent for assaying hBTC and as a diagnostic agent for diabetes and
CC  its complications. It offers a highly sensitive assay for hBTC, and has
CC  low toxicity
XX
SQ  Sequence 80 AA;

Query Match          100.0%; Score 453; DB 1; Length 80;
Best Local Similarity 100.0%; Pred. No. 2e-36;
Matches 80; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 DGNSTRSPETNGLLCGDPEENCAATTTQSKRKGFHSRCPKQYKHYCIKGRCRFVVAEQTP 60
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 DGNSTRSPETNGLLCGDPEENCAATTTQSKRKGFHSRCPKQYKHYCIKGRCRFVVAEQTP 60

Qy      61 SCVCDEGYIGARCERVDLFY 80
        ||||||||||||||||
Db      61 SCVCDEGYIGARCERVDLFY 80
<!--EndFragment-->

```